# Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB

> **NCT01320943** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 43 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** TDF
- **OTHER:** Stop TDF

## Key facts

- **NCT ID:** NCT01320943
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-26
- **Primary completion:** 2016-07-28
- **Final completion:** 2016-08-23
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2017-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01320943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01320943, "Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01320943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*